<DOC>
	<DOCNO>NCT01843998</DOCNO>
	<brief_summary>The purpose study determine whether sirolimus reduces symptoms cutaneous T-cell lymphoma ( CTCL ) whether cause side effect .</brief_summary>
	<brief_title>Therapeutic Efficacy Topical Sirolimus Early Stage Cutaneous T-cell Lymphoma ( CTCL )</brief_title>
	<detailed_description>This prospective , non-randomized , open label study topical sirolimus treatment CTCL recurrent refractory least one previous skin direct treatment . The purpose evaluation safety anti-tumor response evaluate serial skin examination . Study duration : For subject least partial remission , treatment continue maximum 6 month . All subject follow 6 month time discontinuation study drug progression disease new treatment CTCL start .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Clinically histologically confirm diagnosis CTCL ( early stage disease patch and/or thin plaque cover 10 % , stage IA ) Relapsed refractory disease least one standard skin direct treatment include corticosteroid , topical bexarotene , phototherapy All subject must 18 year age old Life expectancy â‰¥ 6 month , determine treat physician Signed informed consent Patients currently receive anticancer therapy receive anticancer therapy within 4 week start study drug ( include topical systemic glucocorticosteroids , chemotherapy , radiation therapy , antibody base therapy , etc . ) Prior treatment investigational drug within precede 4 week Patients receive chronic , systemic treatment corticosteroid another immunosuppressive agent . Female patient pregnant breast feeding , adult reproductive potential use effective birth control method . Adequate contraception ( oral contraceptive ( `` pill '' ) , intrauterine device ( IUDs ) , contraceptive implant skin , contraceptive injection , diaphragms spermicide condom foam ) must use throughout trial 8 week last dose study drug ( woman childbearing potential must negative urine within 7 day prior administration sirolimus ) . Patients receive prior treatment mTOR inhibitor ( e.g. , sirolimus , temsirolimus , everolimus ) . Patients know hypersensitivity sirolimus rapamycin ( e.g. , everolimus , temsirolimus ) excipient History noncompliance medical regimen Patients unwilling unable comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Early stage</keyword>
	<keyword>Stage 1A</keyword>
	<keyword>Cutaneous T-cell Lymphoma</keyword>
	<keyword>CTCL</keyword>
</DOC>